Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Leukemia, Lymphoid 1Bronchiolitis Obliterans Syndrome 1

Interventions

ibrutinib 6pirtobrutinib 2blinatumomab 2tozasertib 1ofatumumab 1oblimersen 1obinutuzumab 1mocetinostat 1lucatumumab 1forodesine 1fenebrutinib 1enzastaurin 1Mitoxantrone 1Epoetin Alfa 1Bendamustine Hydrochloride 1Antineoplastic Agents 1ARQ531 12-(2-oxo-2-((3,7,11-trimethyl-2,6,10-dodecatrienyl)oxy)aminoethyl)phosphonic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester sodium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Lymphoid × fenebrutinib × Clear all
NCT01991184 2022-06-21

A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.

Genentech, Inc.

Phase 1 Completed
24 enrolled
LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoid, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡